1. Repositório PUCRS

Browsing by Author André Poisl Fay

Skip to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing rec. 28 to 47 of 65   ◄ previous       next ►  
Issue DateTitleAuthor(s)
2018Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh; CHOUEIRI, T. K.; B ogorek, et al
2017Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic ModelDE VELASCO, GUILLERMO; CULHANE, AEDÍN C.; André Poisl Fay, et al
2022Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515)BASTOS, DIOGO A.; GONGORA, ALINE BOBATO LARA; DZIK, CARLOS, et al
2019Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaNASSAR, AMIN H; HAMIEH, LANA; GRAY, KATHRYN P., et al
2016Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell CarcinomaKWIATKOWSKI, D. J.; CHOUEIRI, T. K.; André Poisl Fay, et al
2022-Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil-JARDIM, DENIS L.; GONÇALVES E SILVA, ADRIANO; POMPEO, ALEXANDRE SAAD FERE LIMA, et al
2016Número necessário a tratar (NNT) e custo por evento evitado (COPE) de enzalutamida e acetato de abiraterona para o tratamento de câncer de próstata resistente à castração que falharam a terapia de privação de androgênioSTEFANI, STEPHEN; SASSE, ANDRÉ; André Poisl Fay, et al
2016Número necessário a tratar (NNT) e custo por evento evitado (COPE) de enzalutamida e acetato de abiraterona para o tratamento de câncer de próstata resistente à castração que falharam a terapia de privação de androgênioSTEFANI, STEPHEN; SASSE, ANDRÉ; André Poisl Fay, et al
2020PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic RegionDE BACCO, MATEUS W.; CARVALHAL, GUSTAVO F.; MACGREGOR, BRADLEY, et al
2015Perioperative Therapy for Muscle Invasive Bladder CancerLEOW, JEFFREY J.; André Poisl Fay; MULLANE, STEPHANIE A., et al
2016Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaDE VELASCO, GUILLERMO; GRAY, KATHRYN P.; HAMIEH, LANA, et al
2016Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaDE VELASCO, GUILLERMO; GRAY, KATHRYN P.; HAMIEH, LANA, et al
2016Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaMAHONEY, KATHLEEN M.; JACOBUS, SUSANNA; BHATT, RUPAL S., et al
2022Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancerAGARWAL, NEERAJ; AZAD, ARUN; SHORE, NEAL D, et al
2015Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré Poisl Fay; SIGNORETTI, SABINA; CALLEA, MARCELLA, et al
2015Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré Poisl Fay; SIGNORETTI, SABINA; CALLEA, MARCELLA, et al
2016Quality of life of cancer patients on the wave of immunotherapyRAMOS, FERNANDA B. PRUSKI; André Poisl Fay
2016Quality of life of cancer patients on the wave of immunotherapyRAMOS, FERNANDA B. PRUSKI; André Poisl Fay
2023Rapid and low-cost liquid biopsy with ATR-FTIR spectroscopy to discriminate the molecular subtypes of breast cancerPEREIRA DE SOUZA, NIKOLAS MATEUS; MACHADO, BRENDA HUNTER; PADOIN, LICERIO VICENTE, et al
2019Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgeryDE CÁSSIO ZEQUI, STÊNIO; DA COSTA, WALTER HENRIQUES; KORKES, FERNANDO, et al
Showing rec. 28 to 47 of 65   ◄ previous       next ►